Web Research
What the Internet Knows About Yatsen
The Bottom Line from the Web
External evidence reveals three things filings alone cannot: (i) a US$120 million Trustar-led convertible-plus-warrants placement announced March 11, 2026 in which CEO Jinfeng Huang personally co-invests — a powerful insider-alignment signal but with a US$4.63/ADS conversion price and a 3-year put that creates a real dilution-and-refinancing overhang on a US$275M market cap; (ii) the FY2025 skincare pivot worked at the gross-margin line (78.2% GM, skincare 53% of mix, net loss cut 87%), but the win is contradicted by a Q4 2025 S&M-to-revenue ratio of 64.8%, up from 60.1% a year earlier — brand pull remains weak when global peers crowd the festivals; (iii) the 2022 securities class action was dismissed without prejudice in August 2024, removing the largest live legal overhang dating back to the Perfect Diary Q2/Q3 2021 disclosures.
What Matters Most
1. US$120 million convertible-plus-warrants placement led by Trustar Capital, with CEO Jinfeng Huang personally co-investing (Mar 11, 2026)
The single most important non-filing event of the year. RMB-denominated convertible senior notes (US$120M aggregate, two equal tranches) at 1.5% coupon, initial 364-day maturity auto-extending to 5 years upon receiving the NDRC foreign-debt registration certificate. Conversion price US$4.63 per ADS (~20% premium at announcement). Cashless warrants for 10% of converted shares struck at US$0.50 per ordinary share (US$10 per ADS). A holder put option exists at year 3 for ~4% IRR. Proceeds tagged for R&D, supply chain, overseas expansion, and potential M&A. CEO co-investment was reviewed and approved by the Audit Committee.
ir.yatsenglobal.com, Mar 11, 2026 · SEC 6-K · stocktitan.net
Why this leads: A US$120M raise on a US$275M market cap is balance-sheet defining. The insider co-investment is bullish optics, but the 3-year put and the warrant strike (US$0.50/share) create overhangs that an ADS-only investor reading the FY2025 20-F would not see. The NDRC certificate is a real near-term gate.
2. FY2025: Revenue +26.7%, skincare crosses 50% of mix, net loss cut 87%
Full-year 2025 net revenues of RMB 4.30 billion (+26.7% YoY). Skincare revenue grew 63.5% YoY and now represents 53% of total revenue. Gross margin rose to 78.2% from 77.1%. Full-year net loss reduced 87% to RMB 92.4 million. The strategic pivot is delivering at the gross-margin line.
Variant lens: The headline numbers validate the multi-year skincare premiumization. The question for the next 4 quarters is whether the mix can keep moving and whether the S&M ratio (see Finding 3) bends down.
3. Q4 2025 S&M expense ratio spiked to 64.8% of revenue — brand pull still thin during peak season
In Q4 2025, selling and marketing expenses reached RMB 893.8 million, or 64.8% of net revenues, up from 60.1% in Q4 2024. The increase was driven by heightened competition during the Double 11 festival. For full-year 2024, S&M was already 66.9% of revenue per third-party analysis. Full-year 2025 operating cash flow was a use of RMB 94.7 million, indicating the GM tailwind has not yet translated into cash conversion.
PR Newswire FY2025 results · Pestel-analysis.com · Yahoo Finance Q4 transcript notes
Contradiction with consensus: the bull thesis assumes operating leverage. Q4 actually saw S&M intensity worsen YoY. Watch Q2 2026 (post-618) for whether this is structural or cyclical.
4. The 2022 securities class action was dismissed in August 2024 — the largest legal overhang is off the table
The class action initiated after the September 2022 Glancy Prongay & Murray investigation — alleging Yatsen misled investors about Perfect Diary's deterioration between Nov 19, 2020 and Mar 10, 2022 — was dismissed without prejudice in August 2024 by Judge Dale E. Ho (S.D.N.Y.). Plaintiffs' motion to file a Second Amended Complaint was denied. This removes a four-year-old contingent liability that the FY2025 20-F note disclosure may treat as merely "concluded."
law.justia.com case docket · Robbins LLP case page
5. Audit Committee Chair Sidney Xuande Huang resigned for "personal reasons" (Feb 28, 2026); Alan Hao Zong added as independent director
Independent director Sidney Xuande Huang (former JD.com CFO, on the YSG board since November 2020) resigned February 28, 2026. The board installed Bonnie Yi Zhang as audit chair and added investor Alan Hao Zong as independent director and key committee member. The stated reason is "personal," not accounting-policy disagreement, and no concurrent Item 5.02-style disclosure of internal-control issues has surfaced.
TipRanks summary · Yatsen IR — Board of Directors
A long-tenured independent director's departure on the same week as the FY2025 results release and 11 days before the Trustar convert announcement is worth watching, even if the disclosures themselves are anodyne.
6. Q1 2026 guidance: revenue growth of +15% to +30% YoY
Management guides Q1 2026 total net revenues to RMB 959 million to RMB 1.08 billion (+15% to +30% YoY). Earnings expected on or around May 14, 2026 per CNBC's earnings calendar. This sets up a binary near-term print, particularly given the 618 festival lands the same quarter management is guiding into.
PR Newswire FY2025 results · CNBC quote page
7. US$30M share repurchase program authorized May 2025 — partial offset to potential convert dilution
The Board authorized a US$30 million share repurchase program effective May 16, 2025, with a 24-month duration, funded by existing cash. If fully executed, the buyback could absorb a meaningful share of the ~26 million ADS equivalents implied by the US$120M convert at the US$4.63 conversion price, but execution pace has not been disclosed in subsequent releases. PR Newswire — Q1 2025 update
8. ADS ratio change to 1:20 effective March 18, 2024 — reverse-split optics
The company changed its ADS-to-Class A ordinary share ratio to 1 ADS = 20 ordinary shares, effective March 18, 2024, which is economically similar to a 1-for-5 reverse ADS split. All per-ADS metrics have been restated. The change came as YSG's ADS price was approaching NYSE minimum-bid-price compliance thresholds. PR Newswire — ADS ratio change
9. Channel asymmetry: C-beauty wins on Douyin; Tmall/JD remain dominated by global brands
Syntun data from both the 2025 618 festival and 2025 Double 11 shows top sales rankings on Tmall and JD.com still skewed toward global brands (Proya, L'Oréal Luxe, Estée Lauder), with C-beauty momentum concentrated on Douyin. This is the structural reason Yatsen's S&M ratio jumps in Q4 — to compete on Tmall it must outspend, and on Douyin it must keep paying for live-stream pit fees.
Jing Daily — 618 reality check · Syntun 2025 Double 11 data · Syntun 2025 618 data
10. Eve Lom impaired twice (RMB 354M in 2023, RMB 403M in 2024) — acquired March 2021 from Manzanita
The Eve Lom acquisition (Space Brands Limited from Manzanita Capital, closed March 30, 2021) has been impaired in two consecutive years — RMB 354M (~US$50M) in Q4 2023 and RMB 403M (~US$55M) in Q4 2024 — implying meaningful capital destruction on the prestige-skincare strategy that anchored the 2021 narrative. Manzanita retained an equity interest at deal close. Cosmetics Business — Eve Lom deal · BeautyMatter coverage · MarketScreener deal completion
Recent News Timeline
What the Specialists Asked
Governance and People Signals
The biggest narrative arc in governance over the past 12 months is the simultaneous arrival of Trustar Capital plus a new independent director (Zong) alongside the exit of the most experienced independent director (Sidney Huang). Whether by coincidence or design, board capital and board composition both shifted in favor of the financing sponsor's network within a 14-day window. That deserves to be flagged even if every individual disclosure reads anodyne in isolation.
The Trustar convert review by the Audit Committee is the textbook governance response to a related-party investment, and the disclosed terms (in particular the warrant strike at US$0.50/ordinary share) are explicit rather than buried. The 3-year put at ~4% IRR is the underappreciated piece: it functions like a soft refinancing trigger if the equity story has not played out by 2029.
Industry Context
External evidence sharpens three industry threads beyond what filings alone can show:
1. The Tmall vs Douyin channel asymmetry is structural, not cyclical. The 2025 618 and Double 11 Syntun briefs both rank Proya, L'Oréal Luxe, Estée Lauder and other global brands at the top of the color and skincare categories on Tmall and JD, while C-beauty momentum is concentrated on Douyin. For Yatsen this is the proximate cause of the Q4 2025 S&M ratio spike — competing on Tmall requires outspending; competing on Douyin requires continuous live-stream pit-fee payments. Either way the marketing intensity does not naturally fall.
2. NMPA "special cosmetics" regulation is moat-positive for compliant local players but the page set returned does not include a 2026-vintage primary view of throughput. Specialist queries flagged this as a real moat-watch question for the FY2025 20-F notes section — the absence of fresh public commentary should not be read as the regulatory tailwind dissipating.
3. C-beauty domestic share thesis (57% in 2024, ~60% in 2026) remains directionally supported by festival data but lacks a 2026-vintage primary Frost & Sullivan / Euromonitor cite. The industry-question for the next 90 days is whether the 618 2026 festival shows global brands clawing back share on Tmall/JD as their FX tailwinds in China stabilize.
All figures expressed in Renminbi (RMB / ¥) for native financial statements, and US dollars ($) for ADS-listed quantities (share price, market cap, convert/warrant terms — the way they are reported to NYSE-listed investors). The companion research-claude-USD.md file presents the same analysis with RMB amounts translated to USD at the relevant period-end rate.